We are live on ! Find out more
OTLK icon

Outlook Therapeutics

77 hedge funds and large institutions have $29.4M invested in Outlook Therapeutics in 2022 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 27 increasing their positions, 18 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 18

40% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 5

1% more funds holding

Funds holding: 76 → 77 (+1)

0.35% less ownership

Funds ownership: 11.01% → 10.66% (-0.35%)

56% less capital inflows, than outflows

Capital inflows: $691K | Capital outflows: $1.56M

Holders
77
Holders Change
+1
Holders Change %
+1.32%
% of All Funds
1.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
27
Reduced
18
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

OTLK Hedge Fund Activity: Q3 2022 in Review

77 of the 5,834 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q3 2022, worth a combined $29.4M — up 16% from $25.4M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new OTLK positions and 5 closed out — a net gain of 2 holders — while 27 added to existing stakes and 18 trimmed.

The largest buyer was Fidelity Investments, opening a new position worth an estimated $188K. The largest seller was Vista Finance, cutting an estimated $724K.

  • 77 institutional investors held Outlook Therapeutics (OTLK) as of Q3 2022, up from 76 in Q2 2022.
  • Funds reported $29.4M of Outlook Therapeutics stock for Q3 2022, up 16% quarter-over-quarter.
  • 7 funds opened new Outlook Therapeutics positions in Q3 2022 and 5 closed out, a net change of +2 holders.
  • The largest Outlook Therapeutics buyer in Q3 2022 was Fidelity Investments, an estimated $188K added.
  • The largest Outlook Therapeutics seller in Q3 2022 was Vista Finance, an estimated $724K sold.

Based on aggregated 13F filings for Q3 2022.